ResultsIQ

ResultsIQ › Latest results › Aurobindo Pharma Limited

Aurobindo Pharma Limited Q4 FY25 results press release summary

NSE: AUROPHARMA · BSE: 524804

Results press release of 26 May 2025, summarised by AI from the filing.

Aurobindo Pharma Q4 FY25 revenue ₹8,382 cr (+10.6% YoY) and net profit ₹903 cr (-0.5% YoY), with US and Europe formulations growth.

Original filing on BSE

Aurobindo Pharma Limited Q1 FY27 results

As filed: Revenue ₹9,150 cr (+16% year on year), EBITDA ₹1,881 cr (+17% year on year), PAT ₹1,032 cr (+25% year on year), EBITDA margin 20.6% (+17 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹8,853 cr (+6% year on year), EBITDA ₹1,753 cr (−2% year on year), PAT ₹921 cr (+2% year on year), EBITDA margin 19.8% (−157 bps). Score 33 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 157 bps year on year. Share price after the results: −3.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹8,646 cr (+8% year on year), EBITDA ₹1,773 cr (+12% year on year), PAT ₹910 cr (+8% year on year), EBITDA margin 20.5% (+73 bps). Score 40 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 73 bps year on year. Share price after the results: +8.4% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹8,286 cr (+6% year on year), EBITDA ₹1,677 cr (+7% year on year), PAT ₹848 cr (+4% year on year), EBITDA margin 20.2% (+15 bps). Score 33 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 15 bps year on year. Share price after the results: +6.0% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹7,868 cr (+4% year on year), EBITDA ₹1,604 cr (−1% year on year), PAT ₹824 cr (−10% year on year), EBITDA margin 20.4% (−101 bps). Score 20 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 101 bps year on year. Consolidated profit -10% but standalone +70%. Revenue fell 6% from last quarter. Revenue rose ₹301 cr on a year ago, against ₹716 cr the year before. Share price after the results: −5.1% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹8,382 cr (+11% year on year), EBITDA ₹1,791 cr (+7% year on year), PAT ₹903 cr (0% year on year), EBITDA margin 21.4% (−69 bps). Score 33 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 69 bps year on year. Share price after the results: −4.9% in 30 days (Nifty 500: +2.7%).
  • Q3 FY25: Revenue ₹7,979 cr (+9% year on year), EBITDA ₹1,578 cr (−1% year on year), PAT ₹846 cr (−10% year on year), EBITDA margin 19.8% (−200 bps). Score 19 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 200 bps year on year. Revenue rose ₹627 cr on a year ago, against ₹945 cr the year before.
  • Q2 FY25: Revenue ₹7,796 cr (+8% year on year), EBITDA ₹1,566 cr (+14% year on year), PAT ₹817 cr (+9% year on year), EBITDA margin 20.1% (+105 bps). Score 51 of 100, In line with trend. EBITDA margin rose 105 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 11% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Aurobindo Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.